Tofacitinib Citrate


Indications and Reactions:

Role Indications Reactions
Primary
Rheumatoid Arthritis 47.1%
Hypertension 14.2%
Prophylaxis 6.9%
Psoriasis 5.8%
Supplementation Therapy 3.1%
Osteoporosis 2.9%
Depression 2.8%
Gastritis Prophylaxis 2.0%
Diabetes Mellitus 1.9%
Gastrooesophageal Reflux Disease 1.7%
Hyperlipidaemia 1.5%
Type 2 Diabetes Mellitus 1.4%
Back Pain 1.3%
Dyslipidaemia 1.3%
Hypercholesterolaemia 1.2%
Pain 1.1%
Asthma 0.9%
Hypothyroidism 0.9%
Prophylaxis Against Gastrointestinal Ulcer 0.9%
Vitamin Supplementation 0.9%
Appendicitis 7.2%
Breast Cancer 7.2%
Pulmonary Embolism 7.2%
Squamous Cell Carcinoma Of Skin 7.2%
Anal Abscess 5.8%
Diverticulitis 5.8%
Sepsis 5.8%
Septic Shock 5.8%
Squamous Cell Carcinoma 5.8%
Transient Ischaemic Attack 5.8%
Basal Cell Carcinoma 4.3%
Chronic Obstructive Pulmonary Disease 4.3%
Gastroenteritis 4.3%
Pneumonia 4.3%
Renal Cell Carcinoma 4.3%
Breast Cancer Female 2.9%
Cerebral Haemorrhage 2.9%
Hypertensive Crisis 2.9%
Intraductal Proliferative Breast Lesion 2.9%
Malignant Melanoma 2.9%
Secondary
Rheumatoid Arthritis 44.2%
Psoriasis 12.0%
Hypertension 7.6%
Prophylaxis 5.6%
Depression 3.6%
Product Used For Unknown Indication 2.4%
Blood Cholesterol Increased 2.0%
Diabetes Mellitus 2.0%
Gastritis Prophylaxis 2.0%
Osteoarthritis 2.0%
Pneumonia 2.0%
Prophylaxis Against Gastrointestinal Ulcer 2.0%
Vitamin Supplementation 2.0%
Anxiety 1.6%
Dyslipidaemia 1.6%
Hypercholesterolaemia 1.6%
Hyperlipidaemia 1.6%
Osteoporosis 1.6%
Renal Transplant 1.6%
Arthralgia 1.2%
Prostate Cancer 10.5%
Vomiting 10.5%
Abdominal Pain 7.9%
Vocal Cord Paralysis 7.9%
Anal Abscess 5.3%
Blood Creatine Phosphokinase Increased 5.3%
Epididymitis 5.3%
Metastases To Liver 5.3%
Necrotising Fasciitis 5.3%
Pulmonary Embolism 5.3%
Skin Ulcer 5.3%
Sleep Apnoea Syndrome 5.3%
Bladder Transitional Cell Carcinoma 2.6%
Breast Cancer 2.6%
Cardiac Failure Congestive 2.6%
Cholecystitis 2.6%
Death 2.6%
Diverticulitis 2.6%
Headache 2.6%
Hepatic Failure 2.6%

Drug Data